WGS
GeneDx Holdings Corp.
$85.77
+0.96
(+1.13%)
Mkt Cap
2.51B
Volume
258,245
52W Range
32.21-170.87
Sector
Healthcare
Beta
1.98
EPS (TTM)
-3.64 USD
P/E Ratio
-178.16
Revenue (TTM)
454.43M USD
Rev Growth (5Y)
+19.0%
EPS Growth (5Y)
N/A
Company Description
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 427.54M | 305.45M | 202.57M | 234.69M | 212.19M | 179.32M | 196.17M |
| Net Income | (21.02M) | (52.29M) | (175.77M) | (548.98M) | (245.39M) | (241.34M) | (29.70M) |
| EPS | -0.73 | -1.94 | -7.23 | -53.63 | -74.93 | -33.16 | -4.26 |
| Free Cash Flow | 14.26M | (33.99M) | (185.86M) | (333.48M) | (211.22M) | (125.10M) | (34.18M) |
| FCF / Share | 0.53 | -1.26 | -7.64 | -32.58 | -64.49 | -22.23 | -6.08 |
| Operating CF | 33.28M | (28.50M) | (180.15M) | (319.15M) | (190.43M) | (93.13M) | (18.73M) |
| Total Assets | 570.19M | 419.38M | 418.76M | 545.26M | 554.09M | 251.64M | N/A |
| Total Debt | 151.95M | 116.17M | 119.77M | 77.13M | 32.85M | 43.26M | N/A |
| Cash & Equiv | 105.00M | 85.21M | 99.68M | 137.40M | 400.57M | 108.13M | N/A |
| Book Value | 308.18M | 245.25M | 228.02M | 253.71M | 388.10M | 4.39M | N/A |
| Return on Equity | -0.07 | -0.21 | -0.77 | -2.16 | -0.63 | -55.00 | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 114.44M | 102.25M | 120.99M | 116.74M | 102.69M | 87.11M | 95.64M | 76.87M | 70.51M | 62.42M | 57.42M | 53.30M |
| Net Income | (17.74M) | (63.32M) | (17.67M) | (7.63M) | 10.81M | (6.53M) | 5.44M | (8.31M) | (29.17M) | (20.24M) | (25.77M) | (42.29M) |
| EPS | -0.60 | -2.16 | -0.61 | -0.27 | 0.38 | -0.23 | 0.20 | -0.31 | -1.10 | -0.78 | -0.99 | -1.64 |
| Free Cash Flow | (39.09M) | (38.86M) | (7.44M) | 9.60M | 8.05M | 4.05M | (6.23M) | (5.04M) | (5.86M) | (16.86M) | (32.23M) | (41.09M) |
| FCF / Share | -1.32 | -1.32 | -0.28 | 0.33 | 0.28 | 0.14 | -0.23 | -0.19 | -0.22 | -0.65 | -1.24 | -1.59 |
| Operating CF | (28.98M) | (32.41M) | (3.09M) | 15.77M | 10.42M | 10.18M | (3.18M) | (4.39M) | (4.50M) | (16.41M) | (29.86M) | (40.98M) |
| Total Assets | 481.49M | 506.30M | 570.19M | 493.90M | 463.86M | 446.43M | 419.38M | 408.84M | 389.10M | 394.53M | 418.76M | 417.29M |
| Total Debt | 167.40M | 168.19M | 151.95M | 113.16M | 114.39M | 114.84M | 116.17M | 116.10M | 116.96M | 123.21M | 119.77M | 73.62M |
| Cash & Equiv | 60.32M | 93.92M | 105.00M | 95.97M | 74.12M | 99.70M | 85.21M | 57.89M | 56.08M | 83.67M | 99.68M | 87.39M |
| Book Value | 244.22M | 254.12M | 308.18M | 292.26M | 277.13M | 257.40M | 245.25M | 204.50M | 194.04M | 207.22M | 228.02M | 254.26M |
| Return on Equity | -0.07 | -0.25 | -0.06 | -0.03 | 0.04 | -0.03 | 0.02 | -0.04 | -0.15 | -0.10 | -0.11 | -0.17 |
WGS News
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
GeneDx Holdings Corp (WGS) Shares Surge 3.3% -- What GF Score of 65 Tells Investors
Short Sellers Are All-In on These 10 Stocks — Squeeze Watch List Inside
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children's
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children's
Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?
GeneDx: Why I Think The Worst Is Behind The Business
Is GeneDx Holdings Corp (WGS) Overvalued After 5.1% Rally? GF Value Says Overvalued
GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy
GeneDx Holdings Corp. $WGS Shares Acquired by Dimensional Fund Advisors LP